Deposition of Foradil P in Human Lungs: Comparison of In Vitro and In Vivo Data

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 17, Issue 1, 2004, Pages 43-49

  Meyer, T ^a   Brand, P ^a   Ehlich, H ^a   Kobrich R ^c   Meyer, G ^d   Riedinger, F ^b   Sommerer, K ^a   Weuthen, T ^a   Scheuch, G ^a  

^a Inamed GmbH   (Germany)

^b Novartis Pharma   (Germany)

^c Salvia Lifetec   (Germany)

^d ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

Author keywords

Dry powder; Formoterol; In vitro; In vivo; Lung deposition

Indexed keywords

AEROLIZER; FORADIL P; FORMOTEROL FUMARATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEVICE; DRUG DELIVERY SYSTEM; DRY DEPOSITION; FEMALE; FLOW RATE; HUMAN; HUMAN EXPERIMENT; INHALATION; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; PEAK EXPIRATORY FLOW; PERFORMANCE; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADULT; BRONCHODILATOR AGENTS; ETHANOLAMINES; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 1942533006     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/089426804322994451     Document Type: Article

References (13)

1. Clark, A.R., and A.M. Hollingworth. 1993. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J. Aerosol Med. 6:99-110.
2. Pedersen, S., and G. Steffensen. 1986. Fenoterol powder inhaler technique in children: influence of inspiratory flow rate and breath-holding. Eur. J. Respir. Dis. 68:207-214.
3. Zanen, P., P.I. Spiegel, and H.V.D. Kolk. 1992. The effect of the inhalation flow on the performance of a dry powder inhalation system. Int. J. Pharm. 81:199-203.
4. Weuthen, T., S. Roeder, P. Brand, et al. 2002. In vitro testing of two formoterol dry powder inhalers at different flow rate. J. Aerosol Med. 15:297-303.
5. Nielsen, K.G., M. Skov, B. Klug, et al. 1997. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur. Respir. J. 10:2105-2109.
6. Lotvall, J., A. Mellen, P. Arvidsson, et al. 1999. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler. Can. Respir. J. 6:412-416.
7. Quanjer, P. H., G. J. Tammeling, J. E. Cotes, et al. 1993. Lung volumes and forced ventilatory flows. Eur. Respir. J. 6:5-40.
8. Pitcairn, G.R., and S.P. Newman. 1997. Tissue attenuation corrections in gamma scintigraphy. J. Aerosol Med. 10:187-198.
9. International Commisssion on Radiological Protection. 1994. Human respiratory model for radiological protection (ICRP Publication 6). Ann. ICRP 24:1-120.
10. Heyder, J., J. Gebhart, G. Rudolf, et al. 1986. Deposition of particles in the human resiratory tract in the size range 0.005-15 μm. J. Aerosol Sci. 17:811-825.
11. Schulz, H., P. Brand, and J. Heyder. 2000. Particle Deposition in the Respiratory Tract. Particle-Lung Interactions. Dekker, New York.
12. de Boer, A.H., D. Gjaltema, and P. Hagedoorn. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138:45-56.
13. Nielsen, K.G., M. Skov, B. Klug, et al. 1997. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur. Respir. J. 10:2105-2109.